Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$1.03
+3.0%
$0.98
$0.80
$2.18
$4.39M0.9670,034 shs55,141 shs
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$0.83
-0.8%
$0.95
$0.59
$8.60
$17.22M0.5673,146 shs5,242 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$1.17
+2.9%
$1.79
$0.67
$2.60
$16.03M1.64416,559 shs88,340 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.46
+4.3%
$1.38
$0.90
$1.96
$17.08M0.5253,555 shs10,579 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00%0.00%0.00%+6.74%-20.77%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00%+6.28%-36.72%-22.60%-81.65%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%-1.43%-42.22%-22.83%+44.81%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%-1.35%-12.57%+29.20%-0.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.6233 of 5 stars
0.05.00.00.00.00.80.6
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.3586 of 5 stars
3.53.00.00.02.31.70.0
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00
N/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
3.00
Buy$14.001,093.52% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CMND, LSB, NRSN, and SYBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
7/10/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$0.73 per shareN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$85.67M0.20N/AN/A$3.35 per share0.25
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,708.20N/AN/A$1.09 per share1.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$5.26M-$1.100.00N/AN/A-164.79%-71.12%9/15/2025 (Estimated)
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
-$13.93MN/A0.00N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$10.21M-$0.540.00N/AN/AN/A-445.40%9/29/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.510.00N/AN/AN/A-8.09%-5.50%11/11/2025 (Estimated)

Latest CMND, LSB, NRSN, and SYBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/12/2025Q2 2025
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.16N/A-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
1.74
1.74
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.05
1.02
0.75
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.71
2.21
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.63
3.63

Institutional Ownership

CompanyInstitutional Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
52.64%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A4.27 millionN/ANot Optionable
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
77320.77 millionN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1013.67 million9.92 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.35 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$1.03 +0.03 (+3.00%)
Closing price 08/22/2025 03:58 PM Eastern
Extended Trading
$1.00 -0.03 (-2.43%)
As of 08/22/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

LakeShore Biopharma stock logo

LakeShore Biopharma NASDAQ:LSB

$0.83 -0.01 (-0.84%)
Closing price 08/22/2025 03:58 PM Eastern
Extended Trading
$0.82 -0.01 (-0.60%)
As of 08/22/2025 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$1.17 +0.03 (+2.89%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$1.18 +0.01 (+0.60%)
As of 08/22/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.46 +0.06 (+4.29%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.46 0.00 (-0.34%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.